N/A Completed N=37 Randomized Double-blind Basic Science

Forearm Immobilization, Metabolic Health, and Muscle Loss

Healthy

Source: ClinicalTrials.gov NCT03866512 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2024

Primary outcomePrimary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob

Summary

The present study will investigate the impact of altered substrate availability on muscle atrophy, insulin sensitivity and muscle protein synthesis following short-term forearm immobilization

Outcome Measures

Outcome	Result	p-value
PRIMARY Percent Change in Forearm Glucose Uptake	-73; 127; -95	—
SECONDARY Percent Change in Muscle Protein Synthesis	-93; -124; -251	—

Eligibility Criteria

Inclusion Criteria

Males and females 18-40 years of age
Body mass index between 18 and 27

Exclusion Criteria

Any diagnosed metabolic impairment (e.g. type 1 or 2 diabetes)
Any diagnosed cardiovascular disease
Hypertension (≥140 mmHg systolic and/or ≥90 mmHg diastolic)
Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)
Regular use of nutritional supplements
Metallic implants
A personal or family history of thrombosis, epilepsy, seizures or schizophrenia
Any previous motor disorders
Any known disorders in lipid metabolism
Any known disorders in muscle metabolism
Known allergy for Acipimox, beta agonist, or other substances in the tablets
Known sensitivity for sympathomimetic drugs
Known hypokalaemia
Presence of an ulcer in the stomach or gut and/or strong history of indigestion
Known severe kidney problems
Pregnancy
Unable to give consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03866512). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.